0001171843-26-003344
SEC filingBeyondSpring Inc. reported Q1 2026 financial results with continuing operations net loss of $2.4 million, improved from $2.6 million prior year, and highlighted Plinabulin and SEED pipeline advancements.
BeyondSpring's Q1 2026 results from continuing operations showed a net loss of $2.4 million, a slight improvement from $2.6 million in the prior year, primarily due to a $0.6 million decrease in G&A expenses from lower personnel and legal costs, offsetting a $0.2 million rise in R&D driven by drug manufacturing for future studies. Cash position stood at $7.9 million, reflecting ongoing burn in a clinical-stage biotech with no revenue. Discontinued operations related to SEED reported a $4.3 million loss versus prior year income, tied to the pending sale of Series A-1 Preferred Shares. Management emphasized Plinabulin's preclinical data at AACR 2026, demonstrating improved complete response rates, survival, tolerability, and immune modulation in ADC combinations, positioning it as a potential backbone therapy. SEED advanced ST-01156, an RBM39 degrader, into Phase 1 with biomarker-driven strategy, validating the RITE3 platform. These updates signal pipeline progress amid tight liquidity, with no guidance provided.